Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy and Chemotherapy in Marginally Resectable Soft Tissue Sarcomas
NCT03651375Phase 2Unknown
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Feb 2017
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and ifosfamide in soft tissue sarcoma (STS), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: The ratio of en limb-sparing/conservative R0 resections at 24 months. Status: unknown.
02
Drugs
doxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03651375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03651375.